TITLE

Drug patent plan gets mixed reviews

AUTHOR(S)
Butler, Declan
PUB. DATE
February 2009
SOURCE
Nature;2/26/2009, Vol. 457 Issue 7233, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses the reaction to U.S. pharmaceutical company GlaxoSmithKline's (GSK) decision to share some of its patents to increase research efforts into neglected diseases and make its drugs available to the poorest countries through cheaper prices. Topics include an explanation of a patent pool and its usefulness, why companies such as France's Sanofi-aventis finds GSK's proposal too vague, and the preservation of growth markets in least-developed countries (LDCs).
ACCESSION #
36636788

 

Related Articles

  • PATENTS: It's good to share. Giles, Jim // Prospect;Apr2009, Issue 157, p66 

    The article discusses the reputation of pharmaceutical companies and plans to implement a patent pool system. The author suggests that the system would allow companies to share intellectual property and develop affordable drugs to treat diseases in developing countries. Other topics include...

  • Implications of TRIPs on Pharmaceutical-Biotechnology Industry. Bhaduri, Nilanjana; Mathew, Mary // IIMB Management Review (Indian Institute of Management Bangalore;Jun2004, Vol. 16 Issue 2, p75 

    Discusses the role of Trade Related Intellectual Property Rights (TRIP) in the pharmaceutical and biotechnology industries. Difference between the perspectives of developed and developing countries on patenting; Impact of biotechnology on pharmaceutical research; Options for Indian...

  • Alnylam casts IP into pool. Shaffer, Catherine // Nature Biotechnology;Sep2009, Vol. 27 Issue 9, p785 

    The article reports on the decision of Cambridge, Massachusetts-based biotechnology company Alnylam to donate 1,500 issued or pending patents on RNA interference to the tropical disease patent pool of GlaxoSmithKline (GSK). The GSK program aims to provide access to intellectual property (IP) and...

  • New deal from the World Trade Organisation. Pollock, Allyson M.; Price, David // BMJ: British Medical Journal (International Edition);9/13/2003, Vol. 327 Issue 7415, p571 

    Reports on the supposed resolution of the issue of giving poor countries access to essential medicines without breaching laws on intellectual property by the World Trade Organization (WTO). Past agreements; Allowance of drug companies to charge monopoly prices for essential drugs; Provisions for...

  • Study examines access to Rxs.  // Chain Drug Review;1/7/2013, Vol. 35 Issue 1, p72 

    The article informs about the Access to Medicine Index, an independent initiative exploring efforts of pharmaceutical companies in developing countries that lack reliable access to medicines, in which GlaxoSmithKline PLC secured first ranking for 2012.

  • Patent policy and public health in developing countries: lessons from Japan. Aoki, Reiko; Kubo, Kensuke; Yamane, Hiroko // Bulletin of the World Health Organization;May2006, Vol. 84 Issue 5, p417 

    The article discusses on the implications of the World Trade Organization's Trade-Related Aspects of Intellectual Property Rights Agreement on the public health sector in developing countries. Under the product patent law, local pharmaceutical companies are restricted to copy manufactured drugs...

  • Patent sense. Herrling, Paul // Nature;9/13/2007, Vol. 449 Issue 7159, p174 

    The article discusses the importance of protecting intellectual property with patents for pharmaceutical companies to discover and develop new drugs for the developing countries. A patent is defined as a grant by the state of exclusive rights for a limited time in respect of a new and useful...

  • Domestic Patents - Questions You Should Ask Your Patent Attorney. Pershes, Robert; Wagner, Louis // BioPharm International;Aug2005, Vol. 18 Issue 8, p10 

    Explores the steps in seeking and managing a patent for pharmaceutical products in the U.S. Assessment on the suitability of a drug discovery to be patented; Consideration of the free use provisions of the teachings and protection contained in the patent; Factor posing literal infringement of...

  • Whose Property Is It, Anyway?  // European Pharmaceutical Executive;May/Jun2006, p18 

    The article discusses the need for the pharmaceutical industry to change its attitude towards intellectual property to survive the changing climate of patent rights in Europe. It focuses on the issue of whether the possession of a single patent was sufficient grounds to bring someone else's...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics